Understanding Non-Muscle-Invasive Bladder Cancer
A guide for adults whose bladder cancer has not grown into the muscle of the bladder wall. About 3 out of 4 new bladder cancers fall in this group. The plan has two parts: clearing what is there now with a same-day operation called transurethral resection of bladder tumor (TURBT), and years of scope checks to catch anything new while it is small.
Welcome
You may have heard your doctor say the words "non-muscle-invasive." Your cancer has not reached the muscle layer of the bladder, and the bladder itself can almost always be saved. This guide covers what happens over the next several years.
About 50 to 70 percent of non-muscle-invasive bladder cancer (NMIBC) patients have at least one new tumor show up on a future scope. Fewer than 1 in 10 low-risk cancers ever grow deeper into the muscle, though the number is higher in high-risk disease. Your team will first clear what is there now with a scope-based operation. Then they bring you back for office cystoscopies on a schedule set by your risk group.
This guide pairs with the Cancer Basics guide, which explains the words and ideas that go with any cancer. Read that one first if you have not yet.
How to use this guide. Read it once at your own pace. Highlight what fits and skip what does not. Bring the questions in Chapter 13 to your next visit, and keep the same-day call list from Chapter 12 somewhere you can find it.
What NMIBC means
Non-muscle-invasive bladder cancer means the cancer sits on the inner lining of the bladder. It has not grown into the muscle wall. About 3 out of 4 new bladder cancers are in this group.
The bladder, in layers
The bladder wall has layers, like an onion. From the inside out: a thin lining called the urothelium, a layer of soft tissue under it, a thick muscle layer, and a layer of fat on the outside. Urine sits inside, touching the lining.
Almost all bladder cancers start in the lining. How far the cancer has grown into these layers decides the stage, and the stage changes the whole plan.
The three stages in this group
- Ta. A small finger-like growth from the lining that sticks into the bladder. The most common type.
- T1. The cancer has grown into the soft tissue under the lining, but not yet into the muscle. T1 is more serious than Ta.
- CIS, or carcinoma in situ (also written Tis). A flat, high-grade patch on the lining. It can look red and velvety on a scope. CIS is always considered high-grade and tends to act more aggressively than Ta.
Why "non-muscle-invasive" can mislead you
Many new patients hear "non-muscle-invasive" and assume the cancer is gone after the first operation. At first diagnosis NMIBC is usually not life-threatening, but it tends to return. About half to two-thirds of patients have at least one new tumor on a scope within five years. That is why the follow-up schedule runs as long as it does.
The two words you will hear a lot are recurrence and progression. Recurrence means the cancer comes back, often at the same stage or grade. Progression means it grows deeper or becomes more aggressive. Recurrence is common in NMIBC. Progression is much less common, but it is the reason the surveillance is so steady.
Muscle-invasive is a different disease
If the cancer reaches the muscle layer, it is called muscle-invasive bladder cancer. That is a different conversation, with different treatment, and is not what this guide covers. Your team will tell you clearly which group you are in.
Most NMIBC is controllable but rarely finished after one operation. Saving the bladder typically means an office scope every 3 to 12 months for at least 5 years. For high-risk disease, it often means scopes for life.
How it was found, and the workup
Most people land in a urologist's office because of blood in the urine. The workup that follows is fairly standard, and you have likely already done most of it.
The most common first sign
Blood in the urine that you can see is the most common first sign. Doctors call this gross hematuria. It may be bright red, pink, or the color of weak tea. It may come and go. Most of the time it does not hurt. Any episode in an adult deserves a workup, even if it stops on its own.
Sometimes the blood is found only on a lab test, not by the eye. Doctors call this microscopic hematuria. It has many possible causes, but in adults at risk it also needs a look.
Other things people notice are urgency, going often, burning that feels like a urinary tract infection but does not clear, or pelvic pain. These show up less often as the first sign.
The standard workup
- Urine tests. A simple dip test and a culture to rule out a bladder infection.
- Cystoscopy in the office. A thin scope goes through the urethra to look inside the bladder. Numbing jelly is used, and it is quick. This is the best test for finding bladder cancer.
- Urine cytology. A urine sample is checked for cancer cells. Best at finding high-grade tumors and CIS (a flat type of cancer in the lining).
- CT urogram, or MR urogram. A scan to make sure no tumor is hiding higher up in the kidney or in the tube that drains it.
"They saw it on the scope. Why do I need an operation?"
Office cystoscopy can show a spot. It cannot remove it or get tissue to confirm what it is. That is what the next step does, a procedure called TURBT. The next chapter walks through it.
You are allowed to have it. Bring it to your next visit. Mark the words you do not know. Your team will walk through it with you. The report sets your risk group, and the risk group sets your plan.
For the basics of how cancer is found, what a pathology report says, and what grade and stage mean, see the Cancer Basics guide.
TURBT: the first operation
TURBT stands for transurethral resection of bladder tumor. It is a same-day operation. It removes what your urologist can see, and it gives the pathologist the tissue needed to make a diagnosis.
What happens
TURBT is done in the operating room. You are either fully asleep or numb from the waist down. A scope is passed through the urethra into the bladder. A small wire loop, using electric current, shaves the tumor off the lining in pieces. The pieces are sent to pathology. Most people go home the same day or the next morning, often with a catheter for one to three days.
What the pathologist looks for
The report will name the type of cancer, the stage (Ta, T1, or CIS), and the grade (low or high). It will also say whether muscle tissue is present in the sample. Without muscle in the sample, no one can be sure the cancer has not reached it. If muscle is missing in a high-grade or T1 case, a second TURBT is often needed.
The single dose of bladder chemo
For many people with lower-risk tumors, the team puts a single dose of chemotherapy into the bladder within 24 hours of the TURBT. The drug sits for one to two hours, then you void it out. This one-time treatment can lower the chance of an early new tumor by about a third. It is not given to everyone. Heavy bleeding or a suspected hole in the bladder are reasons to skip it.
The second look (re-TURBT)
For some patients, a second TURBT four to six weeks after the first is part of the plan. It is done to make sure nothing was missed and to confirm the depth. It is most often done when:
- The pathology shows high-grade T1 cancer.
- The first sample did not include the muscle layer.
- Visible tumor was left behind because of bleeding or size.
A second TURBT can find more cancer in up to half of high-grade T1 cases. In about 1 in 10, it shows the cancer was actually deeper than it first looked. That changes the plan.
Better lights
Some urologists use a special blue light or narrow-band imaging during a TURBT. These tools make small tumors and flat CIS easier to see. They are not used everywhere, and a standard white-light TURBT is still very good. Ask whether they are available where you are being treated.
Your risk group: low, intermediate, high
Once the pathology is back, your team sorts your case into one of three risk groups. This sets the treatment that follows and the schedule of your future scope visits.
The three groups
Progression to muscle-invasive disease depends on grade. For low-grade Ta tumors it runs about 2 to 6 in 100. For high-grade Ta tumors it runs about 5 to 15 in 100. Carcinoma in situ and T1 high-grade carry higher risk and are why those groups get more aggressive treatment.
Why grade matters
Grade is the look of the cancer cells under the microscope. Low-grade cells look close to normal and tend to behave that way. High-grade cells look very abnormal and tend to act that way. For NMIBC, grade often predicts how the cancer will behave better than stage does.
Two patients with the same diagnosis
Two patients can both be told they have "non-muscle-invasive bladder cancer" and face very different roads. A first-time 1 cm low-grade Ta tumor in a 70-year-old is typically watched with yearly scopes after the TURBT. A multifocal high-grade T1 with CIS in the same patient gets a 6-week course of bacillus Calmette-Guerin (BCG) and maintenance for up to 3 years. That patient also gets scopes every 3 months for 2 years, and an honest conversation about cystectomy.
What changes between groups
- Bladder treatment. Low-risk often needs only the single TURBT dose. Intermediate-risk may get a course of bladder chemo. High-risk usually gets BCG.
- Scope schedule. Low-risk patients have far fewer scope visits over time than high-risk patients.
- When cystectomy comes up. Removing the bladder is almost never on the table in low-risk disease. In high-risk disease, it is one of the options.
"What is my risk group, and how does it change the plan?"
Intravesical therapy
Intravesical therapy means medicine placed straight into the bladder through a catheter. It sits in the bladder for one to two hours, then you void it out. The medicine touches the lining where the cancer is. Most of it stays in the bladder, which keeps side effects local.
The two goals
- Lower the chance the cancer comes back. The main goal for low- and intermediate-risk disease.
- Lower the chance the cancer turns deeper. An added, important goal in high-risk disease.
Low-risk disease
For most low-risk cases, the single dose of bladder chemo given right after the TURBT is the only treatment needed. After that, the plan is regular scope checks.
Intermediate-risk disease
Here, the team will often offer a course of treatment in the bladder, given once a week for six weeks. The most common choices are:
- Mitomycin. A chemo drug put in the bladder. Used for many years.
- Gemcitabine. Another chemo drug put in the bladder. Used alone or with a second drug.
- BCG. A different kind of treatment that works through the immune system. See the next chapter.
After the six-week course, some patients also get a stretch of monthly or quarterly doses to keep the protection going. Your team will talk through which agent fits your case.
High-risk disease
The standard first treatment for high-risk NMIBC is BCG, given as a six-week course followed by a longer stretch of maintenance over up to three years. The next chapter covers BCG in detail.
What a treatment visit feels like
You come in with a comfortably full bladder. A nurse places a small catheter. The medicine goes in. You hold it for one to two hours, often by walking around or shifting position. Then you void. The whole visit is short, but plan a quiet rest of the day. Burning, urgency, and going often for one or two days afterward are common.
For most chemotherapy treatments in the bladder, your team will ask you to drink less right before the visit so the medicine is not too diluted. After the dwell time, drink normally to flush the bladder. Ask your nurse for the specific plan that goes with your drug.
BCG and the shortage
BCG is the main treatment for high-risk NMIBC. It has been used for more than 40 years and works better than any other bladder treatment for this group. It is also in short supply right now, and that has changed how teams use it.
What BCG is
BCG stands for Bacillus Calmette-Guerin. It is a weakened bacterium that started out as a tuberculosis vaccine. When it is placed in the bladder, it triggers a strong immune reaction. That reaction targets cancer cells along the bladder lining.
The schedule
The standard BCG plan has two parts:
- Induction. Six weekly treatments, starting a few weeks after TURBT.
- Maintenance. Three weekly treatments at 3, 6, 12, 18, 24, 30, and 36 months. Maintenance is what makes BCG work best against both recurrence and progression.
What BCG feels like
- Burning, going often, urgency for 1 to 2 days after each dose. Very common. Plan a quiet day.
- A low fever and tiredness on the night of the dose. Common.
- A fever above 100.4°F, chills, joint pain. Less common. Call your team the same day.
- A whole-body BCG reaction. Rare, and treated with TB medicines. Get care right away if it happens.
BCG is not given on the day of a hard catheter placement, a urinary tract infection, or visible blood in the urine. Your nurse will check before each dose.
The BCG shortage
Since around 2012, the US has not had enough BCG to go around. Only one company makes the US supply. A new factory is in the works but not yet open. While supply is tight, teams have adapted in a few ways:
- Split-dose BCG. One vial is divided across two or three patients. The data so far supports that this still works in most cases.
- Saving BCG for high-risk patients. If you are at lower risk, your team may offer bladder chemo instead.
- Gemcitabine plus docetaxel. Two bladder chemo drugs given in a row on the same visit. First used after BCG failed. Now also used up front when BCG is short. Early data looks good, with fewer side effects than BCG in some studies.
If BCG is not available for your course, gemcitabine plus docetaxel has comparable response rates in several large series, and mitomycin has decades of supporting data. Your team will pick the agent that fits your pathology and what your center stocks.
Sit when you void for the first 6 hours. Add a cup of household bleach to the toilet bowl before flushing, and let it sit for 15 minutes. This keeps the live bacteria out of the home sewer. Your nurse will give you the full list.
If BCG does not work
BCG does not work for everyone. When BCG has had a fair trial and the cancer is still there, your team will use the phrase BCG-unresponsive. For decades, the only standard answer was removing the bladder. That has changed.
What "BCG-unresponsive" means
The term has a specific definition that the FDA uses when approving new treatments. You qualify if you had a full course of BCG (the first six weeks plus at least one round of maintenance, or a second six-week course) and one of these is true:
- CIS that came back or did not clear within 12 months.
- A new high-grade Ta or T1 within 6 months.
- High-grade T1 at the first scope after induction.
This exact label opens the door to the newer treatments below. All of them are FDA-approved for this group.
The four options
| Option | How it is given | What is special about it |
|---|---|---|
| Pembrolizumab | IV every few weeks | An immune therapy given through a vein. Works for the whole body, with all the side effects that brings. |
| Nadofaragene firadenovec | In the bladder, every 3 months | A gene therapy placed in the bladder. Mostly local side effects. Quarterly schedule is easier on the calendar. |
| Nogapendekin alfa with BCG | In the bladder, with BCG | An immune booster used together with BCG. Strong response rates in early data. Needs BCG to be available. |
| Radical cystectomy | A major operation | The most definitive option. Removes the bladder. Done with a urinary diversion (see chapter 9). |
How to think about the choice
None of the bladder-saving drugs is a clear winner over the others. There are no head-to-head studies yet. Your team will weigh several things with you:
- What you can tolerate. Immune therapy through a vein has whole-body side effects. Bladder-only options are gentler outside the bladder.
- How often you can come in. Quarterly is much different from every few weeks.
- What is available. Some centers offer all of these. Some refer for a few of them.
- How aggressive your disease has been. A long stretch of high-grade or fast-returning disease may push the conversation toward cystectomy.
- Your own goals. Some people want to do anything to save the bladder. Some are ready to take the surgery and be done with the watching.
A second opinion at a center that sees many of these cases is reasonable here. Treatment options here are changing quickly.
Surveillance, and the long haul
For most people, the bigger part of NMIBC is the years of careful watching that follow the first treatment.
Why the scopes are so frequent
NMIBC comes back often. The whole lining of the bladder was exposed to the same things that caused the first tumor, and small changes the eye cannot see can be there too. Cystoscopy is the tool that finds new spots early, when they are still small and easy to treat.
The tools
- Cystoscopy in the office. The main test. Quick, with numbing jelly. Done again and again for years.
- Urine cytology. Often done at the same visit if you are at higher risk.
- Upper tract imaging. A CT or MR urogram every one to two years to check the kidneys and ureters.
- Urine marker tests. Used in some practices as a backup to cystoscopy. Not a substitute for it yet.
How often, by risk group
| Risk group | First 2 years | Years 2 to 5 | After year 5 |
|---|---|---|---|
| Low | Scope at 3 months, then 6 to 9 months | Yearly scope | Often tailored or stopped, by shared decision |
| Intermediate | Scope every 3 to 6 months | Every 6 to 12 months | Yearly out to about 10 years |
| High | Scope every 3 months | Every 6 months | Yearly, often for life |
The week before each scope
Scanxiety is the anxiety that builds in the week before a surveillance cystoscopy. Most people feel some of it. Scheduling the scope for early in the week shortens the wait. Asking for the visual result before you leave the office, instead of waiting on a phone call, keeps the unknown from sitting overnight. If the anxiety is getting in the way of sleep, work, or your relationships, two or three sessions with a therapist who works with cancer patients often helps.
How long the scopes go on
For low-risk disease, the scopes can stop after a few years. For high-risk disease, they often continue for the rest of your life. That is the trade for keeping the bladder. Each scope itself takes 2 to 5 minutes, uses numbing jelly, and most patients are back to normal activity the same day.
New visible blood in the urine, even just a little pink, deserves a call. Do not wait for the next scope.
When cystectomy is on the table
Removing the bladder, called radical cystectomy, is a major operation. It is rarely the first move in NMIBC. It comes up in a few specific situations.
When teams talk about it
- BCG-unresponsive high-risk disease. This is when the bladder-saving options above are not the right fit.
- High-grade T1 with worrying features on the pathology report. For example, the tumor is in blood vessels, has grown deep into the soft tissue under the lining, or is an aggressive cell type.
- High-grade tumors that keep coming back even with BCG and other treatments.
- Patient preference in selected high-risk cases.
Why timing matters
If high-risk NMIBC grows into the muscle before cystectomy, the long-term outlook is much worse than if surgery is done while the cancer is still in the lining. Your team will raise the option once the pattern of recurrences or pathology features make it the better trade, often after a failed course of BCG or after a second worrying pathology.
What the operation involves
- The bladder and nearby lymph nodes come out. In men, the prostate is usually removed at the same time. In women, the uterus, ovaries, and a small part of the vaginal wall may be removed, though many surgeons now spare these in selected cases.
- A new way for urine to leave the body, called urinary diversion, is made.
- Most people spend 4 to 7 days in the hospital and need 4 to 6 weeks at home before they feel close to themselves again.
Three kinds of diversion
- Ileal conduit. A short piece of intestine carries urine to an opening on the belly that drains into a bag. The most common option and often the simplest to live with.
- Continent reservoir. A pouch made from intestine, kept inside the body. You empty it through a small opening on the belly with a thin tube, a few times a day. No bag.
- Neobladder. A new bladder made from intestine and connected to your urethra, so you void close to the way you did before. Most suited to selected patients.
The surgery can be done open, with small ports (laparoscopic), or with a robot. Many busy centers now use the robot. Care at a center that does many of these is a smart move. Ask your doctor for a referral.
Many centers will have you meet a stoma nurse before surgery to walk through what life with each diversion is really like. People who have had each kind can also share their experience. Both are useful before you settle on a choice.
Living with the diagnosis
NMIBC is both a cancer diagnosis and a chronic condition. You and your team will manage it together for years. The next few sections cover the parts of daily life that come up most often after the first treatment is behind you.
Smoking is the biggest single thing you can act on
Smoking causes more than half of bladder cancers and is the strongest single risk factor you can change. Studies on whether quitting after diagnosis lowers the recurrence rate are mixed, but quitting clearly lowers your risk of heart disease, lung disease, and several other cancers, which matters because most NMIBC patients live a long time with the diagnosis. Combining a medication (varenicline, bupropion, or nicotine replacement) with a few sessions of counseling or a quit line roughly doubles the odds of staying smoke-free at one year compared with going it alone. Ask your team for a referral or call 1-800-QUIT-NOW.
Other simple things that matter
- Keep every scope appointment. A missed scope gives a new tumor time to grow.
- Bring a current list of medicines and supplements to each visit.
- Drink enough water. Plain hydration is fine. No need to go to extremes.
- Pay attention to past or current job exposures. Dye, rubber, leather, paint, hairdressing, and aluminum work all have a known tie to bladder cancer. Talk with your team about reducing future exposure.
Anxiety during years of follow-up
Repeated surveillance scopes can keep the diagnosis in mind in a way that other chronic illnesses do not. Two or three sessions with a counselor who works with cancer patients is often enough to take the edge off, especially in the first year. A support group can do the same for some people. The Bladder Cancer Advocacy Network runs a peer-matching program that pairs you with someone who has been through the same treatment. Most cancer centers also have a social worker who can connect you to local resources in a single phone call.
Money and the system
Bladder cancer care over years adds up: scope visits, treatments, scans, and time off work. Your cancer center's social worker can point you to co-pay help, foundation grants, and patient assistance programs. The Family and Medical Leave Act protects time off in many jobs. Ask early.
Sex and intimacy
Cystoscopy can be uncomfortable for a few days. Some people find bladder treatments leave the bladder tender for a stretch. Talking with your partner about timing helps. If a cystectomy is in your future, ask your team about how the operation may affect sexual function and what can be done to protect it.
Common questions
These are the questions patients ask the most, in the order they tend to come up.
Is this going to kill me?
For most NMIBC patients, no. Low-risk Ta cancers rarely turn into a deeper, dangerous cancer. High-risk disease, especially CIS and high-grade T1, is more serious and is treated aggressively to stop that step from happening. Your team can give you a clearer answer for your own case.
Why does it keep coming back?
The whole lining of the bladder was exposed to the same things that caused the first cancer. Small changes the eye cannot see can be there too. Treatment and scopes lower the chance of new spots but do not erase it. Most new spots are caught early and treated with another TURBT.
What is the difference between coming back and getting worse?
Recurrence means a new cancer of the same kind shows up again. Progression means the cancer becomes deeper or more aggressive. Recurrence is common. Progression is much less common.
Why do I need a second TURBT?
In high-grade T1, a second TURBT in 4 to 6 weeks finds more cancer in up to half of cases. In about 1 in 10, it shows the cancer was deeper than first thought.
What if there is not enough BCG?
Your team has options. Split-dose BCG (one vial across two or three patients) works well in many cases. Gemcitabine plus docetaxel given in the bladder is a strong alternative, and mitomycin C is another. None of these is a lesser choice.
What if BCG does not work?
You have four options. Three save the bladder: pembrolizumab by vein, nadofaragene every 3 months in the bladder, and nogapendekin alfa with BCG. The fourth is radical cystectomy. The right choice depends on your case and your goals.
How often will I need cystoscopy?
It depends on your risk group. Low-risk: a few times in the first year, then yearly. Intermediate-risk: every few months for the first year or two, then less often. High-risk: every three months for the first two years, then every six months, then yearly, often for life.
Will I lose my bladder?
Most people will not. Low- and intermediate-risk patients almost never need cystectomy. Most high-risk patients who respond to BCG or other bladder treatments keep their bladders too. Cystectomy comes up when BCG and bladder-saving drugs are not the right fit, or when the cancer has features that push the conversation that way.
Should I quit smoking now, even with the diagnosis I already have?
Yes. The data on whether quitting lowers the chance of recurrence is mixed. The data on whether quitting helps your heart, lungs, and other cancer risk is clear. Ask your team for support.
Should my family be screened?
In most cases, routine tests for your family are not advised. Sometimes a family has a pattern that points to a known cancer-risk gene. One example is several close relatives with colon, uterine, or urinary tract cancer at young ages. If that fits your family, a visit with a genetic counselor is a fair next step.
Do urine marker tests replace the scope?
Not yet. Urine markers can support the scope and help when results are unclear. They are not a substitute for it.
Can I drink coffee, alcohol, or eat spicy food?
None of these cause bladder cancer. They may make you more uncomfortable after a bladder treatment. Use how you feel as your guide.
When to call your team
A simple list of what counts as a same-day call and what can wait for a routine visit. Save this page or take a photo of it.
New visible blood in the urine, especially with clots. Inability to urinate. Fever above 100.4°F, especially in the 24 to 48 hours after a BCG treatment. Severe burning or bladder pain that does not ease with usual measures. New joint pain, rash, or strong tiredness after BCG. New flank pain, especially with fever.
For the office to know about, but not always same-day
- Bladder symptoms that get worse, or last more than one to two days after a treatment.
- A missed or upcoming surveillance visit, especially if you cannot make it.
- Bothering side effects from bladder treatment that get in the way of daily life.
- A new question about smoking-cessation help.
- Questions about a new treatment you heard about, or a clinical trial.
Why "same-day" matters with BCG
A whole-body BCG reaction is rare, but it can happen days after a treatment. Joint pain, fever above 100.4°F, chills, or a sense of being unusually sick deserve a same-day call, not a wait-and-see. The treatment for this is straightforward when it is caught early.
A note about urgent care and the ER
When you go to an urgent care or the ER, tell them you are on bladder cancer treatment. If you are getting BCG, say so. If you have had a TURBT recently, say so. These details change what they look for and the antibiotics they choose.
A simple card helps a lot in any ER or urgent care visit. Put your urologist's office number, your treatment, and one line such as "I am getting BCG in the bladder." Ask your team if they have a card you can use.
Questions to ask your team
Bring this page to your next visit. Questions are hard to remember on the spot.
About my cancer
- What is my exact stage and grade?
- Does my pathology show CIS?
- Was muscle in the sample? Do I need a second TURBT?
- What is my risk group, low, intermediate, or high?
About the first plan
- Did I get the single dose of bladder chemo after my TURBT?
- Do I need a course of treatment in the bladder? Which agent, and why?
- If BCG is recommended, is full-dose BCG available, or are you using a split dose?
- What is the alternative if BCG is in short supply or does not fit me?
About the schedule
- How often will I need cystoscopy? For how many years?
- Will I have urine cytology with each scope?
- When will I get my next upper-tract imaging?
If things change
- What does it look like if BCG does not work for me?
- At what point would cystectomy come into the conversation?
- Would a second opinion at a busy center make sense for me?
- Are there clinical trials that fit my situation?
About living with this
- What side effects from treatment need a same-day call?
- Can I see a smoking-cessation specialist?
- Is there a nurse navigator or social worker I can meet?
- What support does your center offer for the long stretch of follow-up?
Words to know
General cancer words live in the Cancer Basics guide. These are the ones used most in bladder cancer care.
- NMIBC
- Non-muscle-invasive bladder cancer. Stages Ta, T1, and CIS.
- MIBC
- Muscle-invasive bladder cancer. A different disease with different treatment.
- Ta
- A finger-like tumor on the lining. The most common kind.
- T1
- A tumor that has grown into the soft tissue under the lining, but not into the muscle.
- CIS (Tis)
- Carcinoma in situ. A flat, high-grade patch on the lining.
- Urothelial carcinoma
- The most common type of bladder cancer cell. Older name: transitional cell carcinoma.
- Hematuria
- Blood in the urine. Visible to the eye is gross; seen only on a lab test is microscopic.
- Cystoscopy
- A look inside the bladder with a thin scope through the urethra.
- TURBT
- Transurethral resection of bladder tumor. A scope-based operation that removes the tumor and gives tissue for diagnosis.
- Re-TURBT
- A second TURBT 4 to 6 weeks after the first, in selected cases.
- Muscularis propria
- The thick muscle layer of the bladder wall. Cancer that reaches it is muscle-invasive.
- Intravesical therapy
- Medicine placed straight into the bladder through a catheter.
- BCG
- A weakened bacterium that triggers an immune attack on cancer cells. The main treatment for high-risk NMIBC.
- Induction
- The first set of treatments, usually six weekly doses.
- Maintenance
- Spaced-out doses that follow induction to keep protection going.
- Mitomycin C
- A bladder chemotherapy used after TURBT or as a course.
- Gemcitabine
- A bladder chemotherapy used alone or with docetaxel.
- Gem/Doce
- Gemcitabine followed by docetaxel in the bladder on the same visit.
- BCG-unresponsive
- A defined situation where adequate BCG has been given but disease persists or comes back in a set window.
- Pembrolizumab
- An immune therapy given by vein. Approved for BCG-unresponsive CIS.
- Nadofaragene
- A gene therapy placed in the bladder every 3 months. Approved for BCG-unresponsive disease.
- Nogapendekin alfa
- An immune booster used in the bladder with BCG. Approved for BCG-unresponsive CIS.
- Radical cystectomy
- An operation to remove the bladder, with a urinary diversion.
- Ileal conduit
- A short piece of intestine that carries urine to a stoma on the belly.
- Neobladder
- A new bladder built from intestine and connected to the urethra.
- Continent reservoir
- An inside pouch that you empty with a small tube through an opening on the belly.
- Cytology
- A microscope check of urine for cancer cells.
- Urine marker tests
- Lab tests like Cxbladder or UroVysion that look for cancer-related changes in urine.
- Recurrence
- Cancer that shows up again after a period clear.
- Progression
- Cancer that becomes deeper or more aggressive than before.
- Risk group
- Low, intermediate, or high. Sets your treatment and your follow-up schedule.
- Scanxiety
- Anxiety in the days before a surveillance scope or scan. Common.
Sources and further reading
This guide draws on current society guidelines and the major trials behind today's standard of care. The list below is where to read more.
- EAU 2025 NMIBC Guidelines. uroweb.org
- Bladder Cancer Advocacy Network (BCAN). bcan.org
- BCAN BCG Shortage Resource. bcan.org/bcg-shortage-bladder-cancer
- Sequential intravesical gemcitabine and docetaxel (Steinberg et al). pubmed.ncbi.nlm.nih.gov
- Gem/Doce versus BCG comparative cohort (JAMA Network Open). pubmed.gov
- KEYNOTE-057, pembrolizumab in BCG-unresponsive CIS (Lancet Oncology). pubmed.gov
- FDA approval summary, nadofaragene firadenovec. aacrjournals.org
- FDA approval summary, nogapendekin alfa inbakicept. pmc.ncbi.nlm.nih.gov
- SEER Cancer Stat Facts: Urinary Bladder. seer.cancer.gov
- American Cancer Society: Bladder Cancer Risk Factors. cancer.org
- NCI: Bladder Cancer. cancer.gov
- ClinicalTrials.gov. clinicaltrials.gov
- National Society of Genetic Counselors (find a counselor). nsgc.org
Always work through your own situation with your care team. The numbers and choices in this guide are population averages and the right answer for you depends on your pathology, your other health conditions, and your own preferences. Use this guide to come prepared with questions, and let the conversation with your urologist do the rest.